Haijing Wu - Central South University

Haijing Wu

Central South University

China

Haijing Wu - Central South University

Haijing Wu

Introduction

Primary Affiliation: Central South University - China

Publications

5Publications

28Reads

251Profile Views

25PubMed Central Citations

The emerging role of circulating microRNAs as biomarkers in autoimmune diseases.

Autoimmunity 2014 Nov 23;47(7):419-29. Epub 2014 Jun 23.

Department of Dermatology, The 2nd Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenetics , Changsha , China .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08916934.2014.929667DOI Listing
November 2014
2 Reads
11 Citations
2.714 Impact Factor

The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Clin Rev Allergy Immunol 2014 Oct;47(2):219-33

Hunan Key Laboratory of Medical Epigenetics, Department of Dermatology, Second Xiangya Hospital, Central South University, #139 Renmin Middle Rd, Changsha, 410011, Hunan, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12016-014-8439-6DOI Listing
October 2014
3 Reads
8 Citations
5.463 Impact Factor

Cell-based therapies for systemic lupus erythematosus

Volume 14, Issue 1, January 2015, Pages 43–48

Autoimmunity Reviews

Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease characterized by multi-organ disorders. The pathogenesis of SLE is complex. Corticosteroids and immunosuppressive drugs are widely used to treat patients with SLE. However, these indiscriminate suppressors of the immune-mediated inflammatory aberration treat SLE at the cost of considerable adverse effects. Undoubtedly, there is a need for safer and more effective treatments for SLE. Cell-based therapies, although very much in their infancy, are of increasing interest in the treatment of SLE due to their potential for long-term suppression or a possible cure of the disease. Several immunoregulatory cell types, including regulatory T cells, mesenchymal stem cells, B-cells and natural killer cells, have recently been developed as novel products for tolerance-promoting therapies. Here, we provide a brief overview of current research of new cell-based therapeutic approaches that have undergone pre-clinical or clinical trials in the treatment of SLE.

View Article
October 2014
6 Reads

The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus.

2010 Oct;37(10):2046-52. doi: 10.3899/jrheum.100293. Epub 2010 Aug 3.

J Rheumatol

OBJECTIVE: Interleukin 17 (IL-17) was recently linked to pathogenesis of systemic lupus erythematosus (SLE), but its relation to disease activity has not been well characterized. We examined the relation between serum levels of Th17 (IL-17, IL-23), Th1 (IL-12, interferon-γ), Th2 (IL-10, IL-6, IL-4) cytokines and disease activity in patients with SLE. METHODS: Serum cytokines were measured by enzyme linked immunosorbent assays. Disease activity was determined by SLE disease activity index (SLEDAI), anti-dsDNA antibody, and C3 and C4 levels. RESULTS: Serum levels of IL-17 (p < 0.001), IL-6 (p = 0.006) and IL-10 (p < 0.001) were higher in SLE patients (n = 70) compared to healthy controls (n = 36). Higher serum IL-23 level was found in patients with active disease with cutaneous manifestations (p = 0.004) and serositis (p = 0.04) compared to those without. Serum IL-17 level above the detection limit was more frequently found in patients who had active lupus nephritis (11/23, 47.8%) (p = 0.002), nonrenal active disease (9/15, 60%) (p = 0.001), and inactive lupus (21/32, 65.6%) (p < 0.001) compared to healthy controls (0%). Serum IL-17 levels were otherwise comparable between these 3 groups of patients and were not related to SLEDAI, glomerular filtration rate, activity or chronicity score and ISN/RPS criteria class among patients with active lupus nephritis. There was no significant correlation between serum IL-17/IL-23 and Th1 or Th2 cytokine levels. CONCLUSION: SLE patients had higher serum IL-17 levels than healthy controls. Elevated serum IL-23 was found in patients with inflammatory manifestations including cutaneous involvement and serositis. The lack of correlation between Th17, Th1, and Th2 cytokines suggested independent regulatory mechanisms for these cytokines.

View Article
October 2010
1 Read

Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia.

Immunol Invest 2009 ;38(5):408-21

College of Pharmacy, School of Medicine, Soochow University, Suzhou, China.

View Article

Download full-text PDF

Source
December 2009
23 Reads
6 Citations
1.903 Impact Factor